Acadia pharmaceuticals receives complete response letter from u.s. fda for supplemental new drug application for pimavanserin for the treatment of hallucinations and delusions associated with alzheimer's disease psychosis

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that the company has received a complete response letter (crl) from the u.s. food and drug administration (fda) regarding its supplemental new drug application (snda) for nuplazid® (pimavanserin) for the treatment of hallucinations and delusions associated with alzheimer's disease psychosis (adp). the crl indicated that the fda has completed review of the application, determining that it could not approve the
ACAD Ratings Summary
ACAD Quant Ranking